Sugi Predict

Sugi Predict / Compounds / SCHEMBL185994

SCHEMBL185994

SCHEMBL185994

CN(C)c1ncc(C(=O)O)cn1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 1.00
▸ KDM4E B2RXH2 2/20 1.00
▸ HSD17B10 Q99714 2/20 1.00
▸ ALOX15 P16050 1/20 1.00
▸ HPGD P15428 2/20 0.53
▸ MEN1 O00255 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ P4HA1 P13674 2/20 0.45
▸ P4HTM Q9NXG6 2/20 0.45
▸ HCAR2 Q8TDS4 1/20 0.44
▸ MIF P14174 1/20 0.43
▸ HCAR3 P49019 3/20 0.43
▸ GRM5 P41594 2/20 0.42
▸ GABRP O00591 1/20 0.42
▸ GABRD O14764 1/20 0.42
▸ GABRA1 P14867 1/20 0.42
▸ GABRB1 P18505 1/20 0.42
▸ GABRG2 P18507 1/20 0.42
▸ GABRB3 P28472 1/20 0.42
▸ GABRA5 P31644 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23407776 0.82 KDM4E (0.69) ALDH1A1KDM4EHSD17B10ALOX15HPGD
SCHEMBL4771472 0.80 KDM4E (0.67) ALDH1A1KDM4EHSD17B10ALOX15HPGD
SCHEMBL17611243 0.77 KDM4E (0.62) ALDH1A1KDM4EHSD17B10ALOX15P4HA1
SCHEMBL6982188 0.77 ALDH1A1 (0.61) ALDH1A1KDM4EHSD17B10ALOX15HPGD
SCHEMBL27968622 0.75 ALDH1A1 (0.59) ALDH1A1KDM4EHSD17B10ALOX15HPGD
SCHEMBL4886683 0.75 ALDH1A1 (0.58) ALDH1A1KDM4EHSD17B10ALOX15HPGD
SCHEMBL185995 0.74 ALDH1A1 (0.59) ALDH1A1KDM4EHSD17B10ALOX15HPGD
SCHEMBL185619 0.73 ALDH1A1 (0.58) ALDH1A1KDM4EHSD17B10ALOX15HPGD
SCHEMBL17075550 0.73 KDM4E (0.56) ALDH1A1KDM4EHSD17B10ALOX15HCAR3
SCHEMBL185127 0.72 HCAR3 (0.65) ALDH1A1KDM4EHSD17B10ALOX15HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025085689-A1 EXTRACELLULAR SMALL MOLECULE ACTIVATORS TARGETING BESTROPHIN CHANNELS FOR DISEASE TREATMENT THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2025-04-24 — — WO claimed
WO-1995029897-A1 METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS G.D. SEARLE & CO. (US) 1995-11-09 — — WO claimed
WO-2026087442-A1 AMINO-IMIDAZOLE ANTIBACTERIAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2026-04-30 — — WO disclosed
US-20250214970-A1 PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS XENON PHARMACEUTICALS INC. (CA) 2025-07-03 — — US disclosed
WO-2025085689-A1 EXTRACELLULAR SMALL MOLECULE ACTIVATORS TARGETING BESTROPHIN CHANNELS FOR DISEASE TREATMENT THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2025-04-24 — — WO disclosed
EP-4405334-B1 SORTILIN INHIBITORS SORTINA PHARMA AB (SE) 2025-02-12 — — EP disclosed
US-20250002460-A1 SORTILIN INHIBITORS SORTINA PHARMA AB (SE) 2025-01-02 — — US disclosed
EP-4405334-A1 SORTILIN INHIBITORS Sortina Pharma AB (SE) 2024-07-31 — — EP disclosed
CN-118317947-A Sortilin inhibitors 索蒂纳制药股份有限公司 2024-07-09 — — CN disclosed
US-11912686-B2 LPA receptor antagonists and uses thereof GILEAD SCIENCES, INC. (US) 2024-02-27 — — US disclosed
US-11912686-B2 LPA receptor antagonists and uses thereof GILEAD SCIENCES, INC. (US) 2024-02-27 — — US disclosed
US-6972297-B2 2-Hydroxy-mutilin carbamate derivatives for antibacterial use SMITHKLINE BEECHAM P.L.C. (GB) 2005-12-06 — — US disclosed
CN-1210267-C 2-hydroxy-mutilin carbamate derivatives for antibacterial use SMITHKLINE BEECHAM PLC (GB) 2005-07-13 — — CN disclosed
CN-1427827-A 2-Hydroxy-mutilin carbamate derivatives for antibacterial use SMITHKLINE BEECHAM PLC (GB) 2003-07-02 — — CN disclosed
US-20030114674-A1 2-Hydroxy-mutilin carbamate derivatives for antibacterial use SMITHKLINE BEECHAM P.L.C. (GB) 2003-06-19 — — US disclosed
EP-1268443-A1 2-HYDROXY-MUTILIN CARBAMATE DERIVATIVES FOR ANTIBACTERIAL USE SmithKline Beecham p.l.c. (GB) 2003-01-02 — — EP disclosed
WO-2001074788-A1 2-HYDROXY-MUTILIN CARBAMATE DERIVATIVES FOR ANTIBACTERIAL USE SMITHKLINE BEECHAM PLC (GB) 2001-10-11 — — WO disclosed
US-4144339-A TREATMENT OF BILHARZIASIS RHONE-POULENC INDUSTRIES (FR) 1979-03-13 — — US disclosed
US-4138487-A NEMATOCIDES RHONE-POULENC INDUSTRIES (FR) 1979-02-06 — — US disclosed
US-4110450-A BILHARZIASIS RHONE-POULENC INDUSTRIES (FR) 1978-08-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030114674-A1 2-Hydroxy-mutilin carbamate derivatives for antibacterial use MSH6, MSH2, PMS2 ALDH1A1 1967/4885KDM4E 1084/4885HSD17B10 1578/4885
US-20250002460-A1 SORTILIN INHIBITORS SORT1, GRN, SCARB1 ALDH1A1 3576/4885KDM4E 4845/4885HSD17B10 1828/4885
US-20250214970-A1 PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS SCN1A, SCN3A, SCN2A ALDH1A1 1110/4885KDM4E 2085/4885HSD17B10 3346/4885
US-11912686-B2 LPA receptor antagonists and uses thereof LPAR1, LPAR2, LPAR4 ALDH1A1 1726/4885KDM4E 2095/4885HSD17B10 1457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.